Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RUVBL1 | Q9Y265 | 4/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393207 | 0.86 | MAOA (0.49) | — | |
| SCHEMBL1393206 | 0.83 | SOS1 (0.41) | SOS1OPRM1OPRK1RUVBL1KRAS | |
| SCHEMBL1394413 | 0.76 | MAOA (0.48) | — | |
| SCHEMBL1394410 | 0.76 | MAOA (0.48) | — | |
| SCHEMBL1393444 | 0.75 | MAOA (0.53) | — | |
| SCHEMBL3087603 | 0.74 | CCKBR (0.50) | MAPT | |
| SCHEMBL11983300 | 0.73 | MAOA (0.51) | MAPT | |
| SCHEMBL4811525 | 0.73 | MAOA (0.50) | — | |
| SCHEMBL1394408 | 0.72 | MC5R (0.42) | OPRM1OPRK1 | |
| SCHEMBL3087601 | 0.72 | CTSL (0.51) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | SOS1 2589/4885OPRM1 1815/4885OPRK1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.